Angela Stathopoulos
Psychiatric/Mental Health · Lansing, MINPI 1306096193
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 43.6% of the total. Reporting peaked in 2022 at $4,815 and has fallen 81.2% since, to $904 in 2025. Among psychiatric/mental health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $35.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$4K
- Otsuka America Pharmaceutical, Inc.$567
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$491
- Axsome Therapeutics, Inc.$451
- Teva Pharmaceuticals USA, Inc.$418
- Takeda Pharmaceuticals U.S.A., Inc.$353
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$2,63031%
- Travel & lodging$83110%
- Food & beverage$5,01659%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,477 in reported general payments places this provider in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 27 | $26,490 |
| Vilazodone Hcl | 11 | $2,611 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $1,938 |
| Bupropion XlBupropion Hcl | 54 | $1,668 |
| Olanzapine | 33 | $1,552 |
| Aripiprazole | 26 | $817 |
| Prazosin Hcl | 21 | $695 |
| Lamotrigine | 46 | $670 |
| Buspirone Hcl | 17 | $567 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $552 |
| Divalproex Sodium | 12 | $530 |
| Clonazepam | 63 | $504 |
| Quetiapine Fumarate | 28 | $500 |
| Lorazepam | 51 | $395 |
| Nortriptyline Hcl | 25 | $378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $353 | $26,49027 claims |
| Almatica Pharma LLCSertraline Hcl | $26 | $20520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Other psychiatric/mental health in Lansing
- Michele HurlbutLansing$7K
- Duren GutierrezSouthfield$207K
- Tamlynn EvansTraverse City$78K
- Shiba NixonClarkston$60K
- Amy AmesClinton Township$43K
- Cody ShinavierClarkston$41K
- Oksana LidkeBattle Creek$30K
- Jennifer Wims-MaddenPontiac$28K
- Jessica ShantzWarren$21K
- Gladys KimeliSaginaw$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.